Mental health care is as essential as physical health care, and finding the right treatment can significantly improve quality of life. Conditions like anxiety, depression, trauma and stress are common and treatable, especially when addressed early. However, therapy is not one-size-fits-all. Individual needs can shift over time due to life changes, hormonal transitions or ongoing challenges, meaning that finding the right approach may require exploring multiple options.
A variety of evidence-based treatments are available, each serving different needs. Cognitive Behavioral Therapy (CBT) and Dialectical Behavior Therapy (DBT) focus on improving thought patterns, emotional regulation and coping skills, while Eye Movement Desensitization and Reprocessing (EMDR) and somatic therapy help process trauma on both mental and physical levels. For more complex or treatment-resistant conditions, options like Transcranial Magnetic Stimulation (TMS) and ketamine treatment offer alternative approaches, with ketamine therapy providing rapid, though sometimes temporary, relief from depression symptoms. With the added accessibility of telehealth and integrated care, individuals have more opportunities than ever to find a personalized path to mental wellness.
Discover effective ketamine treatment for depression in Charleston, SC, at the Charleston Ketamine Center. Led by Dr. Richard Bowen, this innovative therapy offers rapid relief for individuals struggling with treatment-resistant depression and anxiety when traditional antidepressants have failed. With over 30,000 infusions administered, patients often report significant improvement in symptoms like persistent sadness, fatigue, and hopelessness — sometimes within days rather than weeks.
Experience a calm, medically supervised ketamine infusion process in a comfortable setting. Many patients achieve an 80% response rate for depression and 90% for anxiety, with results that can last months. If you’re searching for ketamine therapy in Charleston or Mount Pleasant that truly works, contact Dr. Bowen today to see if this life-changing treatment is right for you.
For over 50 years, ketamine has been known as a safe anesthetic, and at lower doses, an effective treatment for depression. Emerging research suggests it may also enhance cognition and neuroplasticity, offering hope for patients with neurological disorders such as Parkinson’s, multiple sclerosis, and brain injury. Animal studies show ketamine promotes synaptogenesis and improved memory, while human research remains limited. Combining ketamine with cognitive rehabilitation may enable not only symptom relief but also potential restoration of lost cognitive function.
A retrospective study of 153 patients with severe treatment-resistant depression found that twice-weekly IV ketamine over 4–5 weeks led to faster and greater symptom reduction than intranasal esketamine, with overall tolerability similar. IV ketamine produced significant improvement after the first session, while IN esketamine’s effects emerged after the second. Final depression scores decreased 49.8% with IV ketamine versus 39.5% with IN esketamine. Dropout rates and side effects were comparable, highlighting both as valuable neuropsychiatric tools.
A four-year Cleveland Clinic study of 1,034 patients found that low-dose ketamine infusions significantly improved pain, sleep, and daily function for 20%–46% of people with chronic pain, with benefits lasting up to six months. Nearly half reported reduced pain-related anxiety, and 80% returned for repeat treatments. The therapy was safe, with rare side effects. Researchers say ketamine offers a promising, non-opioid option for chronic pain management and may pave the way for future FDA approval.
A Cleveland Clinic study found that low-dose IV ketamine infusions are safe and effective for chronic pain management. Among more than 1,000 patients, 20%–46% saw lasting improvements in pain, physical function, and sleep for at least six months, with minimal side effects. Nearly half reported reduced pain-related anxiety, and 80% returned for additional treatments. Researchers say ketamine offers a promising, non-opioid option for patients with chronic pain who have exhausted other therapies.
Ketamine has emerged as a promising treatment for suicidal ideation (SI) in patients with major depressive disorder (MDD), showing rapid and sustained reductions in suicidality. Studies from 2020–2025 found IV ketamine and esketamine significantly decreased SI for days to weeks, with early responders showing lower suicide risk at three months. While its mechanisms—such as reduced lateral habenula activity—are still being studied, ketamine must be used alongside therapy, monitoring, and comprehensive psychiatric care to ensure safety and effectiveness.
